[1]蒋娟,易亭伍,张瑜,等.非小细胞肺癌的肿瘤干细胞与非肿瘤干细胞中表皮生长因子受体基因异质性的研究[J].第三军医大学学报,2012,34(20):2039-2042.
 Jiang Juan,Yi Tingwu,Zhang Yu,et al.Genetic heterogeneity of EGFR in cancer and non-cancer stem cells from non-small cell lung cancer[J].J Third Mil Med Univ,2012,34(20):2039-2042.
点击复制

非小细胞肺癌的肿瘤干细胞与非肿瘤干细胞中表皮生长因子受体基因异质性的研究(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
34卷
期数:
2012年第20期
页码:
2039-2042
栏目:
论著
出版日期:
2012-10-30

文章信息/Info

Title:
Genetic heterogeneity of EGFR in cancer and non-cancer stem cells from non-small cell lung cancer
作者:
蒋娟易亭伍张瑜兰洁卢铀
四川大学华西医院:肿瘤中心胸部肿瘤科,生物治疗国家重点实验室
Author(s):
Jiang Juan Yi Tingwu Zhang Yu Lan Jie Lu You
Department of Thoracic Oncology, Cancer Center,State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan Province, 610041, China
关键词:
非小细胞肺癌受体表皮生长因子突变干细胞CD133异质性
Keywords:
non-small cell lung cancer receptor epidermal growth factor mutation stem cells CD133 heterogeneity
分类号:
R329.2;R394.3;R734.2
文献标志码:
A
摘要:
目的      研究非小细胞肺癌(non-small cell lung cancer, NSCLC)的肿瘤干细胞和非肿瘤干细胞中表皮生长因子受体(epidermal growth factor receptor,EGFR)基因状态。      方法      收集2010年6月至2011年8月四川省肿瘤医院及四川大学华西医院胸外科NSCLC新鲜手术标本35例,流式细胞术分选出CD133+细胞和CD133-细胞,采用扩增阻滞突变系统(amplification refractory mutation system,ARMS)分别检测EGFR基因突变,观察其有无差异。      结果      35例NSCLC样本中均检测到CD133的表达。35例CD133+细胞中EGFR基因突变检出率为28.6%,腺癌突变率高于鳞癌(P<0.05),而在不同性别、年龄、有无吸烟史中无统计学差异(P>0.05);CD133-细胞中EGFR基因突变检出率为42.9%,腺癌、无或少吸烟史者突变率高(P<0.05),而不同性别、年龄的突变率无统计学差异(P>0.05)。11例患者标本的CD133+/-细胞存在EGFR基因异质性,占31.4%(11/35)。24例患者标本CD133+/-细胞的EGFR基因状态相同(18例患者中CD133+和CD133-细胞EGFR基因均为野生型,6例患者中CD133+和CD133-细胞EGFR基因为相同的敏感性突变)。      结论      NSCLC患者中CD133+细胞和CD133-细胞中存在EGFR基因异质性。
Abstract:
Objective      To investigate the genetic status of epidermal growth factor receptor (EGFR) in cancer stem cells (CSCs) and non-cancer stem cells from non-small cell lung cancer (NSCLC).       Methods      Thirty-five NSCLC surgical fresh specimens were collected in our department and the Second Peoples’ Hospital of Sichuan Province from June 2010 to August 2011. CD133-positive cells and CD133-negative cells were sorted by flow cytometry after CD133 staining. Amplification refractory mutation system (ARMS) was employed to detect the presence of EGFR mutations in the 2 types of cells. The correlation of the EGFR mutations in different cells was analyzed.       Results      CD133-positive cells were detected in all collected specimens. The EGFR mutation rate was 28.6% in CD133-positive cells, which was higher in adenocarcinomas than in squamous cell carcinomas (P<0.05). But there was no significant difference among different gender, age or smoking history (P>0.05). The EGFR mutation rate was 42.9% in CD133-negative cells, which was higher in adenocarcinomas, and non- or slight-smokers (P<0.05). There was no significant difference between different gender, or age (P>0.05).  There were 11 specimens out of 35 which had EGFR gene heterogeneity in both CD133-positive cells and CD133-negative cells (11/35, 31.4%). The remaining 24 specimens had the same EGFR gene status in both CD133-positive cells and CD133-negative cells (18 cases exhibited EGFR wild type in both CD133-positive and -negative cells, and 6 cases displayed activating EGFR mutations regardless of CD133 expression).       Conclusion      There are EGFR genetic heterogeneity existing between CD133-positive cells and CD133-negative cells in NSCLC.

参考文献/References:

蒋娟, 易亭伍, 张瑜, 等. 非小细胞肺癌的肿瘤干细胞与非肿瘤干细胞中表皮生长因子受体基因异质性的研究[J]. 第三军医大学学报,2012,34(20):2039-2042.

相似文献/References:

[1]杨庆羚,刘翩,王斌,等.EGFR-TKIs治疗晚期非小细胞肺癌并发间质性肺炎4例报告并文献复习[J].第三军医大学学报,2012,34(20):2060.
 Yang Qingling,Liu Pian,Wang Bin,et al.Interstitial pneumonia in EGFR-TKIs-treated non-small-cell lung cancer: report of 4 cases and review of the literature[J].J Third Mil Med Univ,2012,34(20):2060.
[2]斯晓燕,张力.西妥昔单抗联合化疗一线治疗非小细胞肺癌20例临床观察[J].第三军医大学学报,2012,34(20):2063.
 Si Xiaoyan,Zhang Li.Outcomes of cetuximab combined with chemotherapy as first line therapy in 20 patients with non-small cell lung cancer[J].J Third Mil Med Univ,2012,34(20):2063.
[3]罗虎,罗丹,宫亮,等.联合CIK细胞与化疗对比单纯化疗治疗中晚期非小细胞肺癌的Meta分析[J].第三军医大学学报,2012,34(20):2119.
[4]张瑞萍,吴继华,黄英武,等.循环肿瘤细胞检测指导老年非小细胞肺癌个体化治疗1例[J].第三军医大学学报,2012,34(22):2248.
[5]郑英如,李力,刘宝英,等.人可溶性增殖诱导配体促HeLa细胞增殖作用的研究[J].第三军医大学学报,2007,29(20):1951.
 ZHENG Ying-ru,LI Li,LIU Bao-ying,et al.Soluble a proliferation-induced ligand promotes proliferation of HeLa cells[J].J Third Mil Med Univ,2007,29(20):1951.
[6]闫霞,曹官铭,王导新.吉西他滨联合卡铂治疗老年非小细胞肺癌的临床评价[J].第三军医大学学报,2007,29(19):1913.
 YAN Xia,CAO Guan-min,WANG Dao-xin.Gemcitabine plus carboplatin regimen in treatment of advanced non-small cell lung cancer in aged patients[J].J Third Mil Med Univ,2007,29(20):1913.
[7]闵发胜,陈正堂.人非小细胞肺癌与外周血淋巴细胞表达LRP的相关性研究[J].第三军医大学学报,2007,29(17):1699.
 MIN Fa-sheng,CHEN Zheng-tang.Correlation between expression of lung resistance-related protein in non-small cell lung cancer and that in peripheral blood lymphocytes[J].J Third Mil Med Univ,2007,29(20):1699.
[8]高娟,饶进军,吴少瑜,等.丁酸钠与顺铂联用对非小细胞性肺癌细胞生长的抑制作用[J].第三军医大学学报,2007,29(11):1066.
 GAO Juan,RAO Jin-jun,WU Shao-yu,et al.Combination of sodium butyrate and cisplatin has antiproliferative effects on non-small lung cancer cell line[J].J Third Mil Med Univ,2007,29(20):1066.
[9]宋翠淼,杜惠兰,马爱蕊,等.乌鸡白凤口服液对雄激素致不孕大鼠子宫内膜及肌层的影响[J].第三军医大学学报,2007,29(12):1265.
[10]郑顺利,杨庆生,马小红.非小细胞肺癌患者纵隔淋巴结和外周血中MUC1基因的检测及意义[J].第三军医大学学报,2006,28(24):2472.

更新日期/Last Update: 2012-10-18